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We present a strategy to obtain milligrams of highly post-translationally modified eukaryotic proteins,
transiently expressed in mammalian cells as rigid or cleavable fusions with a mammalianized version
of bacterial maltose-binding protein (mMBP). This variant was engineered to combine mutations that
enhance MBP solubility and affinity purification, as well as provide crystal-packing interactions for
increased crystallizability. Using this cell type-independent approach, we could increase the expression
of secreted and intracellular human proteins up to 200-fold. By molecular replacement with MBP, we
readily determined five novel high-resolution structures of rigid fusions of targets that otherwise defied
crystallization.
 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
X-ray crystallography is 100 years old and great advances have
been made in structural biology since the first protein structures
appeared in the fifties. However, because the folding and function
of many biologically and medically relevant human proteins is
dependent on their correct post-translational modification, these
molecules remain difficult to produce in bacteria and thus hard
to investigate biochemically and structurally. Most strikingly,
although more than 50% of native proteins are glycosylated and
this is often crucial for their activity, less than 5% of Protein DataBank (PDB) structures contain covalently-bound carbohydrate
chains (Lütteke and von der Lieth, 2009). In the case of human
proteins, which account for more than 30% of the PDB, under-
representation of post-translationally modified structures is
largely a consequence of the fact that approximately 70% of unique
PDB chains derive from bacterially-expressed material (Berman
et al., 2000).
Mammalian cells are in principle the expression system of
choice for producing properly folded, biologically active human
proteins. However, this approach is still seldom used in structural
biology because of the time required for stable cell line generation,
the high price of commercial formulations for transient transfec-
tion and the limited yield of recombinant protein. Adoption of
polyethylenimine (PEI) as a transfection reagent has considerably
reduced costs and time consumption (Aricescu et al., 2006), and
fusion to highly expressed mammalian carriers secreted by stable
lines (Leahy et al., 2000; Lo et al., 1998) as well as lentiviral trans-
duction (Bandaranayake et al., 2011) can increase protein yields.
Nevertheless, proteolytic separation of mammalian fusion partners
is required for structural studies, and general use of lentivirus-
based systems is hindered by biosafety and construct size limita-
tions. T4 lysozyme fusions have also been exploited successfully,
but their use has so far only been applied to G protein-coupled
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previous structural information, crystallographic phasing of
proteins expressed in mammalian cells still largely relies on the
use of heavy atom soaks, anomalous signal derived from sulfur-
containing Cys and Met residues or – albeit more rarely due to cell
toxicity and reduced yield – selenomethionine incorporation.
Using a horizontal synthetic gene transfer approach, we inves-
tigated whether fusion to MBP – a highly successful bacterial
expression method (di Guan et al., 1988; Lebendiker and Danieli,
2011) – could be applied in mammalian cells in order to solve
the aforementioned issues. MBP is a powerful solubility enhancer
that often helps folding of fusion partners (Needle and Waugh,
2014), can be used both as a detection and a purification tag
(di Guan et al., 1988; Lebendiker and Danieli, 2011), and has been
exploited to facilitate the crystallization and phasing of an
increasing number of rigidly fused passenger proteins (Center
et al., 1998; Cherry et al., 2013; Kobe et al., 2015; Laganowsky
et al., 2011; Monné et al., 2008; Moon et al., 2010; Smyth et al.,
2003; Waugh, 2015).
In this manuscript we report that fusion to MBP significantly
enhances mammalian cell expression of complex eukaryotic pro-
teins. This strategy not only increases the solubility and crystalliz-
ability of passenger proteins, but also provides powerful phasing
information for rapidly determining target structures by molecular
replacement.2. Methods
2.1. DNA constructs
A DNA fragment encoding mMBP and a multiple cloning site
was synthesized (GenScript) and subcloned into pHLsec (Aricescu
et al., 2006), resulting in pHLmMBP construct 1 (Fig. S1A). All sub-
sequent constructs were generated by PCR cloning using PfuTurbo
DNA polymerase (Agilent Technologies). Restriction site informa-
tion for cloning inserts in frame with sequences encoding the cell
adhesion molecule-like tyrosine phosphatase a (Crypa) signal pep-
tide, mMBP, tobacco etch virus (TEV) protease cleavage site and/or
affinity purification/detection tags may be found in Fig. S1A and B.
Non-mMBP fused constructs were prepared by cloning cDNAs
in frame with the Crypa-encoding sequence of pHLsec using AgeI
and XhoI restriction enzymes. The cDNA encoding ENG-N with
its native signal peptide sequence was cloned between the EcoRI
and EcoRV restriction sites of pHLsec. Unfused N-glycosylation site
mutants of the polymerization region of UMOD were expressed
with an immunoglobulin-kappa signal peptide using pIRES2-
EGFP (Clontech).
For insect cell expression, 6His-mMBP-UMODpXR DNA was
cloned in frame with the adipokinetic hormone (AKH) signal
peptide-encoding sequence of pIEX-5 (Novagen/Merck Millipore),
whereas Crypa-6His-mMBP-UMODpXR DNA was cloned into
pIEX-4 (Novagen/Merck Millipore).2.2. Protein expression
DNA for transfection was prepared using HiSpeed Plasmid Midi/
Maxi kits or EndoFree Plasmid Giga kits (QIAGEN). Human embry-
onic kidney (HEK) 293T or 293S (ATCC CRL-3022) cells were ampli-
fied, transferred to a suitable expression vessel and transiently
transfected using 25 kDa branched PEI, based on a published pro-
tocol (Aricescu et al., 2006). Fresh DMEM medium supplemented
with 4 mM L-Gln (Thermo Fisher Scientific) and – if required –
2% fetal bovine serum (Biological Industries) was added to
90–95% confluent cells using the volumes specified in Table S1
for transfection of 6-well plates (10 cm2/well; Corning), T-flasks(150 cm2; BD Biosciences), ribbed roller bottles (2125 cm2;
Greiner) or cell factories (2528 cm2; Thermo Fisher Scientific).
Transfection mixes were prepared by first combining serum-free
medium and DNA, then adding PEI, and finally incubating the
resulting solution for 10 min at 20 C before adding it to the cells.
Unlike HEK293T cells, HEK293S cells tend to detach from ribbed
roller bottles and were thus preferentially grown in T-flasks or cell
factories. Medium was harvested three days after transfection.
For intracellular protein production, 200 ml FreeStyle 293-F
HEK cells (HEK293F; Thermo Fisher Scientific) were grown in
suspension in FreeStyle 293 Expression Medium (Thermo Fisher
Scientific) in a 1.0 L plastic shake flask (Corning), using a
shaking 8% CO2 incubator. When cells reached a density of
2.5–3.0  106 cells/ml, they were transiently transfected by dilut-
ing them 1:1 with medium containing 3.0 lg/ml plasmid DNA
and 9.0 lg/ml 25 kDa branched PEI. Harvesting was performed
four days after transfection.
Transient transfections of Chinese hamster ovary (CHO)-K1 cells
(American Type Culture Collection) were performed in 6-well
plates with Lipofectamine 2000 (Thermo Fisher Scientific), essen-
tially according to the manufacturer’s instructions.
Sf9 insect cells (Novagen/Merck Millipore) were amplified and
transferred to 6-well plates in Sf-900 II SFM medium (Thermo
Fisher Scientific) supplemented with 5% fetal bovine serum.
Transient transfections were performed using 40 kDa linear PEI
(Polysciences) as transfection reagent. 2 lg DNA was combined
with 100 ll Sf-900 II SFM medium and the same was done for
10 lg PEI. DNA/PEI complex formation was performed by combin-
ing both mixes, followed by incubation for 15 min at room
temperature. After replacing the cell medium with Sf-900 II SFM,
the transfection mix was added drop-wise to the cells. Harvesting
was performed three days after transfection.2.3. Protein detection
Immunoblotting was performed with PentaHis mouse mono-
clonal antibody (1:1000; QIAGEN) and horseradish peroxidase-
conjugated goat anti-mouse IgG (1:10,000; Jackson ImmunoRe-
search Laboratories). Chemiluminescence detection was performed
with Western Lightning ECL Plus (Perkin Elmer). Densitometric
analysis was carried out with ImageJ (Schneider et al., 2012).2.4. Protein purification and deglycosylation
Conditioned medium containing secreted mMBP fusions was
adjusted to 10 mM imidazole, 150 mM NaCl and 20 mM
Na-HEPES pH 8.0 (immobilized metal affinity chromatography
(IMAC) binding buffer I). 10 ml pre-equilibrated Ni–NTA agarose
slurry (QIAGEN) was then added per liter of medium and allowed
to incubate overnight at 4 C using an overhead shaker (Heidolph).
Beads were collected and washed with 20 column volumes of
IMAC binding buffer I. Proteins were batch-eluted with 5 column
volumes of 20 mM Na-HEPES pH 8.0, 150 mM NaCl, 500 mM
imidazole, and concentrated using centrifugal filtration devices
(Amicon). In the case of glycoproteins expressed in HEK293S cells,
concentrated mMBP fusions were deglycosylated with Endogly-
cosidase H (Endo H; 1:10 mass ratio) for 1 h at 37 C in 120 mM
Na/K phosphate pH 6.0 (Sigma–Aldrich). Concentrated material
was applied to a Superdex 200 26/600 size-exclusion chromatogra-
phy (SEC) column attached to an ÄKTAFPLC chromatography sys-
tem (GE Healthcare) and pre-equilibrated with 100 mM NaCl,
20 mM Na-HEPES pH 8.0, 10 mM D-maltose (Sigma–Aldrich). Frac-
tions containing mMBP fusion proteins were pooled, concentrated
and used for crystallization trials. For purification from smaller cell
culture vessels, the same protocol was scaled down linearly.
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more stringent IMAC bead wash step with 20 mM imidazole
was performed during purification of fusions with extended
N-terminal His-tags (pHLmMBP vectors 3–5; Figs. S1A and S3).
Affinity purification of intracellularly-produced human GLI
fusion was enhanced by exploiting the amylose-binding properties
of mMBP. HEK293F cells were harvested and lysed at 4 C using
20 mM Na-HEPES pH 8.0, 50 mM NaCl, 1 mMMgCl2 (IMAC binding
buffer II) supplemented with 1% Triton X-100 (Sigma–Aldrich) and
EDTA-free protease-inhibitor cocktail (Roche). Cell debris was
removed by centrifugation at 4000 x g for 20 min, followed by
filtration using a 0.22 lm filter. Cleared cell lysate was incubated
with 12.5 ml amylose beads (New England Biolabs) per liter at
4 C overnight to bind fusion protein. After washing with 5 column
volumes of IMAC binding buffer II, the mMBP fusion was batch-
eluted with 5 column volumes of IMAC binding buffer II supple-
mented with 20 mM D-maltose (Sigma–Aldrich). Amylose affinity
chromatography was followed by IMAC and optionally SEC as
described above.
2.5. mMBP removal
To separate passenger proteins from mMBP, an 18-residue
linker (GGGSGGGSENLYFQSAAA) was engineered between the
two fusion moieties that is resistant to aspecific proteolysis by
cellular proteases, but can be efficiently cleaved by TEV protease
(pHLmMBP vectors 8–11; Fig. S1A).
For TEV protease digestion experiments, mMBP-fused
UMODpXR was expressed using vector 10 (Fig. S1A). IMAC-eluted
protein was concentrated to approximately 1 mg/ml and the buffer
was adjusted to 10 mM Na-HEPES pH 8.0, 50 mM NaCl. Fusion
protein was digested overnight at 20 C with TEV protease
(Tropea et al., 2009), using a mass ratio of 1:100 (TEV protease:
mMBP fusion). Digested material was then deglycosylated over-
night at 37 C, using 4–8 units peptide N-glycosidase F (PNGase
F; New England Biolabs) per lg fusion protein. For cleavage of
mMBP-GLI produced intracellularly using vector 8 (Fig. S1A), a
1:10 mass ratio (TEV protease:mMBP fusion) was used. Digestion
products were analyzed by SDS–PAGE (Fig. 4) and band identity
was verified by immunoblot (Fig. S5).
2.6. Crystallization
Sitting-drop vapor diffusion crystallization trials were per-
formed with a mosquito crystallization robot (TTP Labtech) using
NeXtal DWBlock (QIAGEN) and Morpheus HT-96 (Molecular
Dimensions) (Gorrec, 2009) crystallization screens. Crystallization
trials were performed both in the presence and absence of Zn
(OAc)2 in a 1:1.5 molar ratio. Purified mMBP-UMODpXR was con-
centrated to 6.5–15.0 mg/ml and crystallized with Zn(OAc)2 in
900 mM Na/K tartrate, Tris–HCl pH 7.0–8.6 at 20 C. Crystals grew
to approximately 300 lm (Fig. 1D) and were then adjusted to 4 C,
after which they were transferred stepwise to mother liquor sup-
plied with 20–30% glycerol before flash cooling in liquid nitrogen.
Crystals of mMBP-fused VERL-Fa, ENG-N and VERL-Fb (Fig. 1D)
readily appeared in both polyethylene glycol- and salt-based con-
ditions; crystals of mMBP-ENG-C (Fig. 1D) grew using a PEG/MPD
precipitant mixture. Notably, crystals of mMBP-VERL-Fa could be
cryoprotected for data collection using a stabilization solution sup-
plemented with 30% maltose, suggesting that the latter may also
work as a cryoprotectant for other MBP fusions.
2.7. X-ray diffraction data collection and structure determination
Data were collected at 100 K at beamlines ID29 (de Sanctis
et al., 2012) and ID23-1 (Nurizzo et al., 2006) of the EuropeanSynchrotron Radiation Facility (ESRF, Grenoble), equipped with
DECTRIS PILATUS 6M-F detectors. 0.1-degree oscillation frames
were integrated and scaled with XDS (Kabsch, 2010).
Molecular replacement was performed with Phaser (McCoy
et al., 2007), using an ensemble of MBP PDB entries 3SET and
3SEX (Laganowsky et al., 2011) as the search model. After obtain-
ing initial molecular replacement phases, density modification
was performed with RESOLVE (Terwilliger, 2004) in the PHENIX
package (Adams et al., 2010) (Fig. 2). Model building was carried
out using Buccaneer (Cowtan, 2006), phenix.autobuild
(Terwilliger et al., 2008) and Coot (Emsley et al., 2010); refinement
and validation were performed with phenix.refine (Afonine et al.,
2012) and MolProbity (Chen et al., 2010), respectively. Figs. 2
and 3 were created with PyMOL (Schroedinger, LLC).
3. Results
3.1. Design of an MBP fusion expression system for mammalian cells
The primary structure of MBP suggests that this protein could
be an optimal fusion partner for expression in mammalian cells,
particularly in the case of secreted targets. This is because, despite
its considerable mass (40 kDa), MBP lacks sites that could be
spuriously N-glycosylated, as well as cysteine residues that may
interfere with the correct formation of disulfide bonds in the pas-
senger. Furthermore, MBP is a globular protein rich in a-helices,
making it a powerful search model for molecular replacement
(Smyth et al., 2003; Waugh, 2015).
Numerous amino acid changes reported to increaseMBP solubil-
ity, maltose binding affinity and crystallizability were combined
into a synthetic open reading frame (ORF) codon-optimized for
mammalian cells (mMBP; Fig. S1B). These include A312V and
I317V, a mutation pair that was found to positively impact expres-
sion and purification of MBP fusion proteins in Escherichia coli by
significantly increasing the yield of MBP and its affinity for maltose
(Walker et al., 2010). Mutations E359A, K362A andD363Awere also
introduced, which can facilitate fusion crystallization by reducing
the flexibility of the linker between MBP and passenger proteins
(Center et al., 1998), as well as allowing the two moieties to pack
against each other (Monné et al., 2008). Other changes were based
on surface entropy reduction, an approach that enhances protein
crystallizability by decreasing surface flexibility (Cooper et al.,
2007). This is achieved by mutation of exposed charged residues
to alanine, and application of this strategy to MBP showed that
mutations D82A, K83A, E172A, N173A and K239A significantly
enhanced crystallization of several MBP fusions (Moon et al.,
2010). Finally, mutation to histidine of a-helical residue pairs
located four positions apart, such as A215/K219, K25/K29 and
E309/K313, was recently used to engineer half-binding sites for
divalent metal ions in MBP. Remarkably, the resulting synthetically
symmetrized variants were found to highly enhance crystallization
by providing metal-dependent crystal-packing interactions
between neighboring MBP molecules (Laganowsky et al., 2011).
Because of its compatibility with a wide variety of crystal contacts
(Laganowsky et al., 2011) and based on previous successful usage in
our laboratory (Cherry et al., 2013), we decided to introduce muta-
tion pair A215H/K219H in our synthetic construct.
Different configurations of signal peptide- and/or tag-encoding
DNA sequences were assembled in frame with the basic mMBP
ORF and cloned into transient expression vector pHLsec (Aricescu
et al., 2006). This generated a family of plasmids expressing mMBP
fusion constructs that can either be secreted or produced intracel-
lularly and contain affinity and detection tags at either terminus
(pHLmMBP; Fig. S1A).
To test whether mammalian cells could efficiently produce
mMBP, we used PEI to transiently transfect HEK293 cells with a
Fig. 1. Mammalian expression, purification and crystallization of mMBP-fused target proteins. (A) Immunoblot with monoclonal anti-5His of unfused and mMBP-fused
proteins secreted from HEK293T cells. All constructs carry a 3Ala linker after mMBP and a 6His-tag at either terminus. Formation of intramolecular disulfides is indicated by a
mobility shift between reducing and non-reducing conditions. 5 ll of medium were loaded, except in lanes marked with an asterisk (20 ll). A red arrowmarks the position of
UMOD ZP-C domain, which is barely detectable when expressed in unfused form. (B) Reducing anti-5His immunoblot of proteins expressed in the cytoplasm of HEK293F
cells. (C) Non-reducing Coomassie-stained gel of 3 lg purified mMBP produced by either HEK293T (lane 1) or HEK293S cells (lane 2), as well as purified secreted (lanes 3–7)
or intracellular (lane 8) mMBP fusion proteins. HEK293S-derived fusions (lanes 3, 5 and 6) were treated with Endo H during purification. (D) Crystals of mMBP-fused proteins.
Fig. 2. Target protein phasing by molecular replacement with mMBP. Top halves of the panels show mMBP molecular replacement solutions in cartoon representation.
rA-weighted, density-modified electron density maps of passenger proteins obtained after molecular replacement are colored blue and contoured at 1.0 r. Red arrows point
to the C-terminus of mMBP to which each passenger protein is fused; black arrows indicate maltose electron density. Bottom halves of the panels are close-ups of the electron
density maps in the top halves, with readily interpretable secondary structure features. Insets showmolecular replacement electron density maps (1.0 r, blue) and difference
maps (2.5 r, green) of the mMBP maltose-binding pocket.
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Fig. 3. mMBP-induced packing in UMODpXR, VERL-Fa, VERL-Fb and ENG-C fusion crystals. (A) The N-terminal His-tags of two molecules, together with a Glu residue of mMBP
and two Zn2+ ions, mediate crystal-packing interactions of mMBP-UMODpXR. Crystals could only be obtained in the presence of zinc, and identity of the ion was confirmed by
an anomalous difference map (5.0 r, red) generated from data collected at the zinc absorption edge (k = 1.28215 Å). Red asterisks show the location of the crystal contact,
whose details are shown in the inset, and the triangle indicates the resulting 3-fold crystallographic axis in the H32 space group. Only the mMBP moieties of fusion proteins
are shown here and in subsequent panels. (B) A crystallographic 2-fold generates a hexamer from the trimer in A, shown here in side view. Two such hexamers pack through
two surface loops that contain entropy reduction mutations (Ala196-Ala197, equivalent to Ala172-Ala173 in Fig. S1). The inset shows an enlarged view of the loop-loop
interaction, which forms the major interaction throughout the crystal. (C and D) Orthogonal views of mMBP packing in crystals of mMBP-fused VERL-Fa. mMBP runs as a
spiral through the crystal, which has space group P6522. (E) mMBP also provides packing interactions to mMBP-fused dimers of VERL-Fb in space group P21. (F and G)
Orthogonal views of mMBP-induced packing interactions in crystals of mMBP-fused ENG-C. mMBP forms stacked spirals that run through the crystal with space group P65.
The arrows in (D) and (F) indicate the C-terminus of mMBP where the target protein sequence starts, protruding outwards.
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protein could be detected in unconcentrated conditioned
medium (Fig. 1A, lane 1) and purified to homogeneity by batch
IMAC and SEC, with a final yield of 15 mg/l (HEK293T cells) or
6 mg/l (HEK293S cells) (Fig. 1C, lanes 1 and 2). By lacking
N-acetylglucosaminyltransferase I, the HEK293S cell line is inca-
pable of synthesizing complex N-glycans (Reeves et al., 2002). As
a result, it secretes Man5GlcNAc2-glycosylated proteins that can
be processed with Endo H to obtain homogeneous material suit-
able for crystallographic studies (Chang et al., 2007).
3.2. Production of mMBP-fused proteins
To evaluate if mMBP could help mammalian production of pas-
senger proteins, secreted fusion constructs were generated for sev-
eral difficult extracellular targets that did not yield material
suitable for structural studies due to low expression, reduced sol-
ubility or lack of diffracting crystals. These included UMODpXR, asoluble variant of the polymerization region of human uromodulin
(UMOD)/Tamm–Horsfall protein, a urinary molecule involved in
kidney protection and hypertension (Rampoldi et al., 2011;
Trudu et al., 2013); the zona pellucida (ZP)-C domain of UMOD; a
fragment of vitelline envelope receptor for lysin (VERL-Fa)
(Swanson and Vacquier, 1997); and the N- or C-terminal region
of human endoglin/CD105 (ENG-N and ENG-C), a type I transmem-
brane glycoprotein involved in angiogenesis (Gougos and Letarte,
1990). C-terminal fusion to mMBP via a 3-alanine linker signifi-
cantly boosted the expression of all targets, up to 200-fold in the
case of UMOD ZP-C (Fig. 1A). Comparable results were obtained
for VERL-Fb (another fragment of VERL that shares 40% sequence
identity with VERL-Fa) and ENG-C (Fig. 1A), as well as by fusing
intracellular proteins (such as cancer-associated human transcrip-
tion factor GLI (Kinzler et al., 1988)) to a non-secreted version of
mMBP (Fig. 1B).
Whereas 3.1 mg of an N-glycosylation mutant of mMBP-VERL-
Fa and 2.6 mg of mMBP-ENG-C could be purified from 1 l of
Fig. 4. Cleavage of secreted and intracellular mMBP fusions with a TEV protease-
sensitive linker. (A) Coomassie SDS–PAGE analysis of a TEV protease digestion
experiment to release UMODpXR from the mMBP fusion partner. Protein was
partially purified by IMAC, digested with TEV protease and deglycosylated with
PNGase F; to compensate for the loss of mass, the amount of cleaved material
loaded was double that of the fusion. White and black arrowheads indicate
deglycosylated UMODpXR and mMBP, respectively. Lanes 1 and 2 are control
PNGase F and TEV protease. (B) Coomassie SDS–PAGE analysis of TEV protease
cleavage of intracellularly expressed mMBP-GLI fusion. Material was affinity-
purified using amylose resin followed by IMAC. White arrowhead: GLI; black
arrowhead: mMBP; gray arrowheads: uncleaved mMBP-GLI. Lane 3: control TEV
protease.
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and 7), mMBP-UMODpXR, ENG-N and VERL-Fb were expressed in
fully glycosylated form. N-glycosylation is essential for secretion
of both the polymerization region of UMOD (Fig. S2) and ENG-N
(Gregory, 2011). After Endo H treatment of HEK293S-derived
material, we obtained 3 mg/l, 7 mg/l and 9 mg/l of pure mMBP-
UMODpXR, mMBP-ENG-N and mMBP-VERL-Fb, respectively
(Fig. 1C, lanes 3, 5 and 6). Intracellular expression of mMBP-GLI
using HEK293F cells yielded 2.5 mg/l of purified material (Fig. 1C,
lane 8).
3.3. Crystallization and structure determination of mMBP-fused
proteins
mMBP fusions of UMODpXR as well as of VERL-Fa, ENG-N, VERL-
Fb and ENG-C readily produced multiple diffraction-quality crystal
forms when screened at 6–20 mg/ml concentrations (Fig. 1D). A
native dataset collected from a single crystal of mMBP-UMODpXR
was processed to 3.2 Å resolution, with overall Rpim and CC1/2
values of 3.8% and 99.9%, respectively (outer shell CC1/2: 43.2%).
Crystals of mMBP fusions of VERL-Fa, ENG-N, VERL-Fb and ENG-C
diffracted to resolutions of 1.8 Å, 2.4 Å, 2.9 Å and 2.7 Å, with Rpim
and CC1/2 values of 2.1% and 100.0% (62.3%), 4.6% and 99.9%
(52.0%), 9.9% and 99.0% (50.3%), 6.2% and 99.8% (66.2%),
respectively.
Molecular replacement using MBP as a search model yielded
translation function Z-scores of 27.7 (mMBP-UMODpXR), 58.2
(mMBP-VERL-Fa), 22.6 (mMBP-ENG-N), 39.9 (mMBP-VERL-Fb)
and 30.1 (mMBP-ENG-C). Statistical density modification produced
maps that showed clear secondary structure for the passenger moi-
ety of the fusions; moreover, the mMBP binding pocket contained
difference density for maltose, which was added during purifica-
tion but coordinates for which were not included in the search
model (Fig. 2).
All structures could be almost entirely autobuilt, and mMBP-
UMODpXR, whose mMBP phasing model corresponded to only
28% of the 150 kDa asymmetric unit content, has been refined
to R = 22.1%, Rfree = 24.6% (PDB ID 4WRN; Bokhove et al., 2016).
Refinement of the other structures is ongoing, and biological impli-
cations will be described elsewhere. Notably, most of the crystal
packing interactions observed in the five structures are mediated
by mMBP; in particular, some involve loop residues mutated to
lower the surface entropy and increase the crystallizability of the
protein, while others depend on contacts made by mMBP, its
N-terminal His-tag and zinc ions from the mother liquor (Fig. 3).
3.4. Cleavable mMBP fusions and expression in other cell lines
For functional studies as well as crystallographic analysis of tar-
gets that have structural homologues in the PDB, maintaining pro-
teins of interest as fusions with mMBP may not always be optimal.
For such cases, we constructed expression vector variants that
encode cleavable linkers (pHLmMBP vectors 7–11; Fig. S1A), which
allow efficient removal of the tag from both secreted and intracel-
lular fusions (Fig. 4).
Yield and purity of cleavable fusions can be further improved by
increasing the length of the N-terminal His-tag to 8 residues
(Fig. S3) and/or by adding a spacer between mMBP and the cleav-
age site to facilitate an additional mMBP-mediated amylose affin-
ity purification step (Fig. 4B). Importantly, the mMBP fusion
system can also be used in CHO-K1 cells, where fusion of UMODpXR
to mMBP increased expression by a factor of six compared to
unfused UMODpXR (Fig. S4A). Finally, transiently transfected Sf9
insect cells also efficiently produce and secrete mMBP-fused pro-
teins (Fig. S4B), demonstrating the remarkable versatility of this
bacterially-derived fusion system. Notably, the mammalian Crypasignal peptide is as efficient as its insect AKH-derived counterpart
to drive mMBP fusion protein secretion by Sf9 cells (compare lanes
3, 5 with 2, 4). This suggests that – at least for initial screening –
mMBP fusion construct ORFs developed for mammalian cell
expression can be directly subcloned into insect expression vectors
with their Crypa-encoding region.
4. Discussion
The high yield of mMBP fusion proteins not only largely meets
the demands of functional and biochemical studies, but also consti-
tutes a significant advantage for the structural investigation of
challenging targets expressed in mammalian cells. By combining
the post-translational modification machinery of HEK293 cells
with the ability of mMBP to both facilitate crystal packing and
phase ‘‘real-life” X-ray diffraction data, we were able to determine
the structure of five complex eukaryotic proteins. Especially the
crystal structure of mMBP-UMODpXR revealed a striking mMBP-
induced crystal-packing interface in which the N-terminal His-
tag and a glutamate residue from mMBP coordinate zinc ions from
the crystallization solution (Fig. 3A). This observation suggests that
crystallization trials of mMBP fusion proteins should also routinely
be performed in the presence of Zn2+, which may additionally be
exploited for experimental phasing (Cha et al., 2012).
Notably, the use of mMBP fusions was essential for all these pro-
jects because none of the protein targets folded correctly in E. coli
nor could they be crystallized when expressed in isolated form in
mammalian cells. In the future, mammalian protein production
exploiting the mMBP fusion system could be further improved by
transfecting new highly expressing cell types, such as PER.C6 and
HKB-11 (Swiech et al., 2012). Finally, our strategy could in
principle be combined with other powerful emerging technologies
such as Daedalus, a lentiviral vector-based expression system
(Bandaranayake et al., 2011) and baculovirus-mediated gene trans-
duction of mammalian cells (BacMam) (Dukkipati et al., 2008).
M. Bokhove et al. / Journal of Structural Biology 194 (2016) 1–7 75. Plasmids
mMBP fusion mammalian expression vectors pHLmMBP-1, 2, 3,
6, 8, 10 and 11 (Fig. S1A) have been made available to the scientific
community through Addgene (http://www.addgene.org; accession
numbers 72343-72349).
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